

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	Security Agreement

**CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type
MONARCH PHARMACEUTICALS, INC.		12/29/2008	CORPORATION: TENNESSEE

**RECEIVING PARTY DATA**

<b>Name:</b>	Credit Suisse, as Agent
<b>Street Address:</b>	11 Madison Avenue
<b>City:</b>	New York
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10010
<b>Entity Type:</b>	Bank:

**PROPERTY NUMBERS Total: 16**

Property Type	Number	Word Mark
Registration Number:	2029430	ACCUDOSE
Registration Number:	3130490	ACCUDOSE
Registration Number:	0616775	CORTISPORIN
Registration Number:	2365721	CORTISPORIN TC
Registration Number:	0581264	KEMADRIN
Registration Number:	1350257	
Registration Number:	1621988	MANTADIL
Registration Number:	1808767	MENEST
Registration Number:	1101912	NUCOFED
Registration Number:	1498288	PEDIOTIC
Registration Number:	2713701	POLYMATRIX
Registration Number:	0806889	PROLOPRIM
Registration Number:	0735573	QUIBRON
Registration Number:	0904178	SEPTRA

OP \$415.00 2029430

Registration Number:	1216341	THALITONE
Registration Number:	1018684	VIROPTIC

**CORRESPONDENCE DATA**

Fax Number: (866)826-5420  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
Phone: 3016380511  
Email: ipresearchplus@comcast.net  
Correspondent Name: IP Research Plus, Inc.  
Address Line 1: 21 Tadcaster Circle  
Address Line 2: Attn: Penelope J.A. Agodoa  
Address Line 4: Waldorf, MARYLAND 20602

ATTORNEY DOCKET NUMBER:	34026
NAME OF SUBMITTER:	Penelope J.A. Agodoa
Signature:	/pja/
Date:	12/30/2008

Total Attachments: 7  
source=34026#page1.tif  
source=34026#page2.tif  
source=34026#page3.tif  
source=34026#page4.tif  
source=34026#page5.tif  
source=34026#page6.tif  
source=34026#page7.tif

EXECUTION COPY

**TRADEMARK SECURITY AGREEMENT**

**(Trademarks, Trademark Registrations, Trademark Applications and Trademark Licenses)**

WHEREAS, Monarch Pharmaceuticals, Inc., a Tennessee corporation (herein referred to as the "**Grantor**") owns, or in the case of licenses is a party to, the Trademark Collateral (as defined below);

WHEREAS, King Pharmaceuticals, Inc. (the "**Borrower**"), the lenders and agents party thereto, and Credit Suisse, as Administrative Agent and Collateral Agent, are parties to a Term Loan Credit Agreement dated as of December 29, 2008 (as amended from time to time, the "**Term Loan Credit Agreement**"); and

WHEREAS, the Borrower, the lenders and agents party thereto and Credit Suisse, as Administrative Agent and Collateral Agent, are parties to Amendment No. 1, dated as of December 5, 2008, to the Credit Agreement, dated as of April 19, 2007 (as so amended and as further amended from time to time, the "**Revolving Loan Credit Agreement**"); and together with the Term Loan Credit Agreement, the "**Credit Agreements**"); and

WHEREAS, pursuant to (i) a Guarantee and Collateral Agreement dated as of December 29, 2008 (as amended and/or supplemented from time to time, the "**Collateral Agreement**") among the Borrower, the Grantor, the other Guarantors (as defined therein) party thereto and Credit Suisse, as Collateral Agent for the Secured Parties referred to therein (in such capacity, together with its successors in such capacity, the "**Grantee**"), and (ii) certain other Security Documents referred to in the Collateral Agreement (including this Trademark Security Agreement), the Grantor has guaranteed certain obligations of the Borrower and secured such guarantee (the "**Grantor's Guarantee**") by granting to the Grantee for the benefit of such Secured Parties a continuing security interest in personal property of the Grantor, including all right, title and interest of the Grantor in, to and under the Trademark Collateral (as defined below);

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor grants to the Grantee, to secure the Grantor's Guarantee, a continuing security interest in all of the Grantor's right, title and interest in, to and under the following (all of the following items or types of property being herein collectively referred to as the "**Trademark Collateral**"), whether now owned or existing or hereafter acquired or arising:

- (i) each Trademark (as defined in the Collateral Agreement) owned by the Grantor, including, without limitation, each Trademark

registration and application referred to in Schedule 1 hereto, and all of the goodwill of the business connected with the use of, or symbolized by, each Trademark; *provided* that no security interest shall be granted in United States intent-to-use trademark applications to the extent that, and solely during the period in which, the grant of a security interest therein would impair the validity or enforceability of such intent-to-use trademark applications under applicable federal law;

(ii) each Trademark License (as defined in the Collateral Agreement) to which the Grantor is a party, including, without limitation, each Trademark License identified in Schedule 1 hereto, and all of the goodwill of the business connected with the use of, or symbolized by, each Trademark licensed pursuant thereto; and

(iii) all proceeds of and revenues from the foregoing, including, without limitation, all proceeds of and revenues from any claim by the Grantor against third parties for past, present or future unfair competition with, or violation of intellectual property rights in connection with or injury to, or infringement or dilution of, any Trademark owned by the Grantor (including, without limitation, any Trademark identified in Schedule 1 hereto), and all rights and benefits of the Grantor under any Trademark License (including, without limitation, any Trademark License identified in Schedule 1 hereto), or for injury to the goodwill associated with any of the foregoing;

subject, in each case, to the terms of the proviso of Section 3(a) of the Collateral Agreement.

The Grantor irrevocably constitutes and appoints the Grantee and any officer or agent thereof, with full power of substitution, as its true and lawful attorney-in-fact with full power and authority in the name of the Grantor or in the Grantee's name, from time to time, in the Grantee's discretion, so long as any Event of Default (as defined in the Collateral Agreement) shall have occurred and be continuing, to take with respect to the Trademark Collateral any and all appropriate action which the Grantor might take with respect to the Trademark Collateral and to execute any and all documents and instruments which may be necessary or desirable to carry out the terms of this Trademark Security Agreement and to accomplish the purposes hereof.

Except to the extent expressly permitted in the Collateral Agreement or the Credit Agreement, the Grantor agrees not to sell, license, exchange, assign or otherwise transfer or dispose of, or grant any rights with respect to, or mortgage or otherwise encumber, any of the Trademark Collateral.

The foregoing security interest is granted in conjunction with the security interests granted by the Grantor to the Grantee pursuant to the Collateral Agreement. The Grantor acknowledges and affirms that the rights and remedies of the Grantee with respect to the security interest in the Trademark Collateral

(NY) 08014/507/IP.SECURITY.AGREEMENT/trademark.security.agreement.Monarch.doc

**TRADEMARK**  
**REEL: 003911 FRAME: 0739**

granted hereby are more fully set forth in the Collateral Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

[Signature page(s) to follow]

IN WITNESS WHEREOF, the Grantor has caused this Trademark Security Agreement to be duly executed by its officer thereunto duly authorized as of the 29<sup>th</sup> day of December, 2008.

MONARCH PHARMACEUTICALS, INC.

By: 

Name: James W. Elrod

Title: General Counsel and Secretary

Acknowledged:

CREDIT SUISSE, CAYMAN ISLANDS  
BRANCH, as Collateral Agent

By: \_\_\_\_\_

Name:

Title:

By: \_\_\_\_\_

Name:

Title:

IN WITNESS WHEREOF, the Grantor has caused this Trademark Security Agreement to be duly executed by its officer thereunto duly authorized as of the 29<sup>th</sup> day of December, 2008.

MONARCH PHARMACEUTICALS, INC.

By: \_\_\_\_\_  
Name: James W. Elrod  
Title: General Counsel and Secretary

Acknowledged:

CREDIT SUISSE, CAYMAN ISLANDS  
BRANCH, as Collateral Agent

By:                     JD Toronto                      
Name: JOHN D. TORONTO  
Title: DIRECTOR

By:                     [Signature]                      
Name: MIKHAIL FAYBUSOVICH  
Title: VICE PRESIDENT

**Schedule 1  
to Trademark  
Security Agreement**

**MONARCH PHARMACEUTICALS, INC.**

**U.S. TRADEMARK REGISTRATIONS**

<b>Trademark</b>	<b>Registration #</b>	<b>Registration Date</b>
ACCUDOSE	2029430	January 14, 1997
ACCUDOSE	3130490	August 15, 2006
CORTISPORIN	616775	November 29, 1955
CORTISPORIN TC	2365721	July 11, 2000
KEMADRIN	581264	October 20, 1953
Kidney Shape and Design	1350257	July 23, 1985
MANTADIL	1621988	November 13, 1990
MENEST	1808767	December 7, 1993
NUCOFED	1101912	September 12, 1978
PEDIOTIC	1498288	August 2, 1988
POLYMATRIX	2713701	May 6, 2003
PROLOPRIM	806889	April 12, 1966
QUIBRON	735573	August 7, 1962
SEPTRA	904178	December 15, 1970
THALITONE	1216341	November 16, 1982
VIROPTIC	1018684	August 26, 1975

**U.S. TRADEMARK APPLICATIONS**

None.

**TRADEMARK LICENSES**

<b>Name of Agreement</b>	<b>Parties (Licensor/Licensee)</b>	<b>Date of Agreement</b>	<b>Subject Matter</b>
Agreement for Purchase and Sale of Assets Relating to Neosporin and Polysporin	Glaxo-Wellcome / Monarch Pharmaceuticals, Inc.	November 14, 1997	Neosporin and Polysporin